Insmed - INSM Stock Forecast, Price & News

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed Price Performance

INSM opened at $27.26 on Friday. The company has a quick ratio of 5.34, a current ratio of 5.93 and a debt-to-equity ratio of 18.65. The company has a market cap of $3.27 billion, a P/E ratio of -7.77 and a beta of 1.91. The company has a 50 day moving average of $21.90 and a two-hundred day moving average of $22.18. Insmed has a 52-week low of $16.41 and a 52-week high of $34.44.

Insmed (NASDAQ:INSM - Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.09. Insmed had a negative return on equity of 154.14% and a negative net margin of 188.04%. The business had revenue of $65.20 million for the quarter, compared to analyst estimates of $58.92 million. During the same period in the previous year, the company earned ($0.94) earnings per share. The company's revenue for the quarter was up 43.6% compared to the same quarter last year. On average, analysts expect that Insmed will post -3.4 earnings per share for the current year.

Analysts Set New Price Targets

INSM has been the subject of a number of recent analyst reports. Morgan Stanley cut their price objective on Insmed from $46.00 to $41.00 and set an "overweight" rating for the company in a research report on Friday, July 15th. The Goldman Sachs Group reduced their price target on Insmed from $56.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th. Finally, Credit Suisse Group boosted their target price on shares of Insmed to $58.00 in a research note on Tuesday, August 9th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $50.86.

Insiders Place Their Bets

In other news, CEO William Lewis sold 216,800 shares of the company's stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $27.84, for a total value of $6,035,712.00. Following the completion of the sale, the chief executive officer now directly owns 256,716 shares of the company's stock, valued at approximately $7,146,973.44. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 314,355 shares of company stock worth $8,279,853. Insiders own 4.63% of the company's stock.